<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172937</url>
  </required_header>
  <id_info>
    <org_study_id>DSCGVHD002</org_study_id>
    <nct_id>NCT02172937</nct_id>
  </id_info>
  <brief_title>Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study</brief_title>
  <official_title>Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy using decidual stromal cell
      therapy for graft versus host disease after allogeneic hematopoietic stem cell
      transplantation. The hypothesis to be tested is that the cells are safe to infuse and that
      they have a positive clinical effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1-2x10^6
      cells/kg at one or more occasions dependent on clinical response.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actuarial survival at six months after first DSC infusion</measure>
    <time_frame>6 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at 28 days after onset of graft versus host disease</measure>
    <time_frame>28 days after inclusion</time_frame>
    <description>Response will be measured as:
Partial response (PR) if the patient has improved one grade in the overall GvH.
Complete response (CR) if the patient is free of GvH.
Non responder (NR) if the patient does not improve after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at 84 days after onset of graft versus host disease</measure>
    <time_frame>Up to 84 days after inclusion</time_frame>
    <description>Response will be measured as:
Partial response (PR) if the patient has improved one grade in the overall GvH.
Complete response (CR) if the patient is free of GvH.
Non responder (NR) if the patient does not improve after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at 168 days after onset of graft versus host disease</measure>
    <time_frame>Up to 168 days after inclusion</time_frame>
    <description>Response will be measured as:
Partial response (PR) if the patient has improved one grade in the overall GvH.
Complete response (CR) if the patient is free of GvH.
Non responder (NR) if the patient does not improve after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Up to 6 months after inclusion</time_frame>
    <description>Adverse effects related to the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe infections</measure>
    <time_frame>Up to one year after inclusion</time_frame>
    <description>Severe bacterial, viral and fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Up to one year after inclusion</time_frame>
    <description>Survival free from relapse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Decidual Stromal Cells as last line treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decidual Stromal Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decidual Stromal Cells thawed in plasma</intervention_name>
    <arm_group_label>Decidual Stromal Cells as last line treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decidual Stromal Cells thawed in human albumin</intervention_name>
    <arm_group_label>Decidual Stromal Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute graft versus host disease grade 2-4.

          -  Are on calcineurin inhibitor and high dose corticosteroids.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <phone>+46858582672</phone>
    <email>olle.ringden@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen Kaipe, PhD</last_name>
    <phone>+46700901052</phone>
    <email>helen.kaipe@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olle Ringdén, MD, PhD</last_name>
      <phone>+858582672</phone>
      <email>olle.ringden@ki.se</email>
    </contact>
    <investigator>
      <last_name>Olle Ringdén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Erkers T, Nava S, Yosef J, Ringdén O, Kaipe H. Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner. Stem Cells Dev. 2013 Oct 1;22(19):2596-605. doi: 10.1089/scd.2013.0079. Epub 2013 Jul 2.</citation>
    <PMID>23701127</PMID>
  </reference>
  <results_reference>
    <citation>Ringdén O, Erkers T, Nava S, Uzunel M, Iwarsson E, Conrad R, Westgren M, Mattsson J, Kaipe H. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells. 2013 Mar;31(3):592-601. doi: 10.1002/stem.1314.</citation>
    <PMID>23307526</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>November 8, 2014</last_update_submitted>
  <last_update_submitted_qc>November 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Olle Ringdén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Decidual Stromal Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

